Search Results
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
[email protected] ____________________ReferencesAroda Vanita R, Buzzetti R, Dalskov M, et al. Efficacy and safety of once-weekly CagriSema in adults with type 2 diabetes inadequately controlled on diet and exercise: a randomised, double-blind,
More news about: NOVO NORDISK INC.
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
Nov;109:105447. doi: 10.1016/j.ebiom.2024.105447. Epub 2024 Nov 4. PMID: 39500010; PMCID: PMC11570325. Tan SH, Wu JL, Zhuo SX, Zhang Y, Wang M. Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies. World J Cardiol. 2026 Feb
More news about: Amgen
Jun 07, 2026, 14:30 ET 頭對頭：埃諾格魯肽體重降幅顯著優於司美格魯肽35%
周減重優勢明確：平均體重降幅較司美格魯肽提升35%，≥10%減重應答率近2倍本次研究在國內17家研究中心共納入了163名成年肥胖患者（體重指數BMI≥30kg/m2），參與者按1:1隨機分組接受同等劑量（2.4mg）的埃諾格魯肽或司美格魯肽每週一次皮下注射1。研究數據顯示：治療20周時，埃諾格魯肽組和司美格魯肽組參與者體重較基線平均降幅分別為12.8%和9.5%（P<0.0001）。體重降幅≥5%的參與者比例，埃諾格魯肽組為99%，司
More news about: 杭州先為達生物科技股份有限公司
Jun 07, 2026, 14:30 ET Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
Living with MASLD/MASH and Obesity The SYNCHRONIZE-MASLD trial enrolled adults with excess weight or obesity (BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² with at least one weight-related health condition) who also have MASLD/MASH, serious fatty liver diseases. Participants were randomly
More news about: American Diabetes Association
Jun 07, 2026, 14:30 ET Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
Semaglutide, ≥10% Weight Loss Response Rate Nearly Twofold HigherThis study enrolled 163 adult patients with obesity (body mass index [BMI]≥30 kg/m²) across 17 research centers in China. Participants were randomized 1:1 to receive once-weekly subcutaneous injections of either ecnoglutide or semaglutide
More news about: Sciwind Biosciences Co., Ltd.
Jun 07, 2026, 11:00 ET Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Foundayo (5.5 mg, 9 mg or 17.2 mg) is superior to placebo in body weight reduction from baseline after 72 weeks in people with a BMI ≥30.0 kg/m² or a BMI ≥27.0 kg/m² with at least one weight-related comorbidity and a history of at least one self-reported unsuccessful dietary effort to lose body weight.ATTAIN-2
More news about: Eli Lilly and Company
Jun 07, 2026, 07:14 ET 世界環境デーに、持続可能性を成果につなげる：工場から家庭まで、水とエネルギーの消費削減に取り組むBeko
tainability Lighthouse（サステナビリティ・ライトハウス）の1つに認定されています。[4]Bekoのエジプト工場は、2024年下半期から稼働しています。総面積114,000m²、生産能力年間150万台の同工場は、廃棄物ゼロの原則に基づいて建設され、従来型施設と比較して最大50%の省エネルギーを達成するよう設計されています。同工場は初年度に、10ブランドにわたる約200種類の製品を生産し、40カ国に輸出しました。[5]Singer Bangladeshの製造施設は、バングラデシュ経済特区にある135,00
More news about: Beko
Jun 06, 2026, 14:54 ET University of Phoenix researchers publish study examining doctoral students' attitudes toward AI chatbots and ChatGPT use in higher education
and decision-making, research methodology, data and AI product innovation, project management, business analytics and learning analytics.Anthony M. Bennett, DM, is an adjunct professor at University of Phoenix, teaching courses in organizational leadership, management, human resources, and research
More news about: University of Phoenix
Jun 06, 2026, 14:30 ET Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
The randomized, double-blind, placebo-controlled trial included 537 participants with recent-onset type 2 diabetes (mean 2.5 years) and a BMI of ≥23 kg/m². Over 40 weeks, participants were randomly assigned to receive a once-weekly injection of 4 mg, 9 mg, or 12 mg of retatrutide, or placebo.Findings
More news about: American Diabetes Association
Jun 06, 2026, 14:30 ET Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
visit one, and are naïve to insulin therapy except for gestational diabetes. Study participants had A1C between ≥7.0% and ≤9.5% and a BMI of ≥23 kg/m2 at visit one. Participants randomized to retatrutide initiated treatment with 2 mg once-weekly and increased the dose in a step-wise approach
More news about: Eli Lilly and Company
Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities. People with diabetes were excluded. OASIS 4 included a 64-week treatment period, including
More news about: NOVO NORDISK INC.
Jun 06, 2026, 09:00 ET New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
https://pubmed.ncbi.nlm.nih.gov/41381175/7 Hepprich, M., Roser, P., Stiebitz, S., Felix, B., Schultes, B., Schmitz, D., Rutishauser, J., Schubert, S., Aberle, J., & Rudofsky, G. (2023). Awareness and knowledge
More news about: Abbott
Jun 05, 2026, 20:30 ET 46 Greenberg Traurig Attorneys Recognized in 2026 IAM Patent 1000
Phillip M. Aurentz: Litigation (Texas)
More news about: Greenberg Traurig, LLP
Jun 05, 2026, 19:30 ET Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026
[email protected]:Mora P, Aroda V, Asong M, et al. Zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist: phase 2b results in T2D. Poster presentation at
More news about: NOVO NORDISK INC.
Jun 05, 2026, 18:30 ET First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
that enrolled 111 adults with type 1 diabetes who were classified as having overweight or obesity (body mass index (BMI) greater than or equal to 27 kg/m²). Participants were randomly assigned to receive acmopatide at doses of 1.8 mg, 4.1 mg, 6.6 mg, or placebo. The study's primary endpoint was change in
More news about: American Diabetes Association
Jun 05, 2026, 18:00 ET FlackTek Adds Industry Veteran Dustin Becker to Expand Reach Across Advanced Manufacturing Markets and Accelerate Innovation-Driven Growth
challenges through innovation, precision, and reliability."Prior to Krayden, Becker held leadership and commercial roles with organizations including 3M, Scott Safety, Jadak, and Universal Packaging Solutions, where he consistently drove revenue growth, expanded strategic accounts, and led high-performing
More news about: FlackTek™
Jun 05, 2026, 15:04 ET Circus Circus Las Vegas ofrece la icónica diversión familiar, entretenimiento y recuerdos inolvidables de verano
del panorama moderno de los casinos. Las sesiones se llevan a cabo los viernes a las 5 p. m., 7 p. m. y 9 p. m.; los sábados a las 3 p. m., 5 p. m., 7 p. m. y 9 p. m.; y los domingos a las 11 a. m., 1 p. m. y 3 p. m. Los cartones tienen un costo inicial de $30 por sesión.Acerca de Circus
More news about: Circus Circus
Jun 05, 2026, 14:43 ET The Inner Circle acknowledges Laura Jacqueline Elleby as a Pinnacle Professional Member Inner Circle of Excellence
Producer in 2020, a place in the Executive Club in 2019, and recognition as a top-producing individual agent, achieving over $15M in production in her second year and $25M by her third. She has also consistently ranked among the Top Ten Agents in Georgia every year since becoming licensed.In 2025,
More news about: The Inner Circle
Jun 05, 2026, 14:23 ET Cellebrite anuncia los próximos eventos para inversores el 10 de junio de 2026
Hora de la presentación:9:00 a. m. Hora del esteFormato:
More news about: Cellebrite
Jun 05, 2026, 12:50 ET GreenCore Solutions Corp. (GSC) Signs Multi-Year Asia BPC Supply Deal as Inbound Agent Traffic Hits Record Levels -- Asia-Pacific Crosses 1 Million Inbound Agent Requests
inbound agent requests for the first time, with overall inbound traffic across the GSC AI Agent Stack up 207% quarter-over-quarter, from 4.23M in Q1 to 12.98M in Q2 to date. Asia-Pacific is now GSC's third regional pillar behind EU and UK and the Americas — at roughly 14.6% of global inbound agent traffic,
More news about: Greencore Solutions Corp.
Jun 05, 2026, 12:04 ET Le groupe XCMG et ZF créent une coentreprise de machines agricoles
compétitives au niveau mondial pour le marché des machines agricoles haut de gamme et renforcer l'industrie chinoise des équipements agricoles », a ajouté M. Yang.ZF (Xuzhou) combinera des normes technologiques mondiales avec des solutions adaptées au marché chinois et se concentrera sur la production
More news about: XCMG Machinery
Jun 05, 2026, 12:00 ET AI, Climate Change Adaptation, and Humanitarian Crisis Response: Planet Classroom Unveils June 2026 Global Film Premieres
societies can build resilient, human-centered solutions. Featuring leading voices including Texas State Climatologist John Nielsen-Gammon of Texas A&M University and the humanitarian work of Chef José Andrés' World Central Kitchen, the films translate urgent global challenges into accessible, action-driven
More news about: Planet Classroom Network
Jun 05, 2026, 11:12 ET America's Antimony Gap Is Washington's Problem -- and NevGold Is Racing to Help Close It
2026.[2] NevGold Corp., "NevGold Commences 20,000 Meter Drill Program at Antimony-Gold Limo Butte Project, Nevada," May 21, 2026; and "Closing of Upsized $42M Brokered Private Placement Financing," May 12, 2026.[3] NevGold Corp., "NevGold Congratulates Perpetua Resources On US$2.9 Billion Loan...,"
More news about: American News Group
Jun 05, 2026, 10:57 ET Au-delà des véhicules électriques, VinFast construit un écosystème technologique pour développer la future mobilité mondiale
pratique et économique vers une mobilité de niveau 4 pour les environnements de circulation très dynamiques et réel de l'Asie du Sud-Est. »M. Igal Raichelgauz, PDG d'Autobrains, a déclaré : « Avec NVIDIA et VinFast, Autobrains présente le premier Agentic niveau 4 : conçu pour gérer la
More news about: VinFast
Jun 05, 2026, 10:13 ET Oridian Capital Partners Named to Inc.'s 2026 Best Workplaces List for Second Consecutive Year
companies. The firm targets entry points in large, stable, fragmented North American markets and drives transformational growth through disciplined M&A consolidation and operational excellence. Oridian is headquartered in Washington, D.C. For more information, visit
More news about: Oridian Capital Partners